BofA Securities analyst Jason Gerberry increased the price target on Intra-Cellular Therapies (NASDAQ:ITCI) to $118 from the previous $110, while maintaining a Buy rating for the company's stock.

Tesla (TSLA) shares are under pressure after Bank of America analysts downgraded the stock to Neutral from Buy, citing ...

On Friday, BofA Securities maintained a Neutral rating on Tata Consultancy Services Ltd. (NS:TCS:IN) with a price target of INR4,200.00. The assessment followed TCS's reported third-quarter ...

This downgrade contrasts with recent upgrades by other analysts. On Monday, New Street Research analyst Pierre Ferragu ...

Nvidia Corp. (NVDA) stock was up more than 1.5% in early morning trade on Thursday after Bank of America (BofA) reiterated it ...

BofA Securities analyst John Murphy downgraded shares of electric-vehicle maker Tesla to Hold, but his new target price implies about 17% upside.

On Friday, BofA Securities maintained a Neutral rating on Tata Consultancy Services Ltd. (NS:TCS:IN) with a price target of INR4,200.00. The assessment followed TCS's reported third-quarter revenue ...

On Tuesday, BofA Securities updated their outlook on JPMorgan Chase & Co. (NYSE:JPM) shares, raising the price target to $280 from the previous $260 while reiterating a Buy rating. The adjustment ...